Myasthenia gravis and myasthenic syndromes. Part II. Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes and botulism

Drugs of Today

Volumn 33, Issue 8, 1997, Pages 543-553

  Henze, Thomas ^a  

^a Kliniken Schmieder   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIARRHYTHMIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM ANTISERUM; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; EDROPHONIUM; GUANIDINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MUSCLE RELAXANT AGENT; PROCAINAMIDE; PYRIDOSTIGMINE; QUINIDINE; QUININE; SEDATIVE AGENT;

AUTOIMMUNITY; BOTULISM; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG INDUCED DISEASE; EATON LAMBERT SYNDROME; ELECTROMYOGRAM; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MUSCLE BIOPSY; MYASTHENIA GRAVIS; NEUROMUSCULAR DISEASE; NEUROMUSCULAR TRANSMISSION; NEUTROPENIA; PATHOPHYSIOLOGY; REVIEW; SEIZURE;

EID: 0030856190     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Lambert, E.H., Eaton, L.M., Rooke, E.D. Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 1956, 187: 612-3.
2. Eaton, L.M., Lambert, E.H. Electromyography and electric stimulation of nerves in diseases of motor unit. Observations on myasthenic syndrome associated with malignant tumors. J Am Med Assoc 1957, 163: 1117-24.
3. Anderson, H.J., Churchill-Davidson, H.C., Richardson, A.T. Bronchial neoplasm with myasthenia. Prolonged apnea after administration of succinylcholine. Lancet 1953, ii: 1291-3.
4. Vroom, F.Q., Engel, W.K. Non-neoplastic steroid responsive Lambert-Eaton syndrome. Neurology 1969, 19: 281.
5. Gutmann, L., Crosby, T.W., Takamori, M., Martin, J.D. The Eaton-Lambert syndrome and autoimmune disorders. Am J Med 1982, 53: 354.
6. Lang, B., Newsom-Davis, J., Wray, D., Murray, N. Autoimmune etiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981, II: 224-6.
7. Motomura, M., Johnson, I., Lang, B., Vincent, A., Newsom-Davis, J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995, 58: 85-7.
8. Lennon, V.A., Kryzer, TJ., Griesmann, G.E. et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. New Engl J Med 1995, 332: 1467-74.
9. Lang, B., Newsom-Davis, J. Immunopathology of the Lambert-Eaton myasthenic syndrome. Semin Immunopathol 1995, 17: 3-15.
10. Fukuoka, T., Engel, A.G., Lang, B., Newsom-Davis, J., Prior, C., Wray, D.W. Lambert-Eaton myasthenic syndrome: I. Early morphological effects of IgG on the presynaptic membrane active zones. Ann Neurol 1987, 22: 193-9.
11. Sanders, D.B. Lambert-Eaton myasthenic syndrome: Clinical diagnosis, immune-mediated mechanisms, and update on therapies. Ann Neurol 1995, 37(Suppl. 1): S63-73.
12. O'Neill, J.H., Murray, N.M.F., Newsom-Davis, J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988, 111: 577-96.
13. Elrington, G.M., Murray, N.M.F., Spiro, S.G., Newsom-Davis, J. Neurologicalparaneoplastic syndromes in patients with small-cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991, 54: 764.
14. Lennon, V.A., Lambert, E.H., Whittingham, S., Fairbanks, V. Autoimmunity in the Lambert-Eaton syndrome. Muscle Nerve 1982, 5: S21-5.
15. Tsuchiya, N., Sato, M., Uesaka, Y. et al. Lambert-Eaton myasthenic syndrome associated with Sjögren's syndrome and discoid lupus erythematosus. Scand J Rheumatol 1993, 22: 302-4.
16. Willcox, N., Demaine, A.G., Newsom-Davis, J., Welsh, K.I., Robb, S.A., Spiro, S.G. Increased frequency of IgG heavy chain marker (Glm2) and of HLA-B8 in Lambert-Eaton myasthenic syndrome with and without associated lung carcinoma. Hum Immunol 1985, 14: 2936.
17. Newsom-Davis, J., Leys, K., Vincent, A., Ferguson, I., Modi, G., Mills, K. Immunological evidence for the co-existence of the Lambert-Eaton myasthenic syndrome and myasthenia gravis in two patients. J Neurol Neurosurg Psychiatry 1991, 54: 452-3.
18. Oh, S.J., Dwyer, D.S., Bradley, R.J. Overlap myasthenic syndrome: Combined myasthenia gravis and Eaton-Lambert syndrome. Neurology 1987, 37: 1411-4.
19. Brenna, A., Curto, N., D'Urso, D., D'Avanzo, F. A neuromuscular transmission disorder: Combined myasthenia gravis and Lambert-Eaton syndrome in one patient. J Neurol Neurosurg Psychiatry 1989, 52: 684-5.
20. Kusunoki, S., Tsuji, S., Inoue, K., Mannen, T. Nagai, Y. Combined features of myasthenia gravis and Eaton-Lambert syndrome: Antiganglioside antibodies in serum. J Neurol Sci 1988, 87: 61-6.
21. Laroche, C.M., Mier, A.K., Spiro, S.G., Newsom-Davis, J., Green, M. Respiratory muscle weakness in the Lambert-Eaton myasthenic syndrome. Thorax 1989, 44: 913-8.
22. Barr, C.W., Claussen, G., Thomas, D., Fesenmeier, J.T., Pearlman, R.L., Oh, S.J. Primary respiratory failure as the presenting symptom in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1993, 16: 712-5.
23. Small, S., Ali, H.H., Lennon, V.A., Brown, R.H. Jr., Carr, D.B., de Armendi, A. Anesthesia for an unsuspected Lambert-Eaton myasthenic syndrome with autoantibodies and occult small cell lung carcinoma. Anesthesiology 1992 76: 142-5.
24. Breen, L.A., Gutmann, L., Brick, H.F., Riggs, J.R. Paradoxical lid elevation with sustained upgaze: A sign of Lambert-Eaton syndrome. Muscle Nerve 1991 14: 863-6.
25. Clark, C.V., Newsom-Davis, J., Sanders, M.D. Ocular autonomic nerve function in Lambert-Eaton myasthenic syndrome. Eye 1990, 4: 473-81.
26. Khurana, R.K., Koski, C.L., Mayer, R.F. Autonomic dysfunction in Lambert-Eaton myasthenic syndrome. J Neurol Sci 1988, 85: 77-86.
27. Heath, J.P., Ewing, D.J., Cull, R.E. Abnormalities of autonomic function in the Lambert Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1988, 51: 436-9.
28. Tim, R.W., Sanders, D.B. Repetitive nerve stimulation studies in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1994, 17: 995-1001.
29. Oh, S.J., Head, T., Fesenmeier, J., Claussen, G. Peroneal nerve repetitive nerve stimulation test: Its value in diagnosis of myasthenia gravis and Lambert-Eaton myasthenic syndrome. Muscle Nerve 1995, 18: 867-73.
30. Leys, K., Lang, B., Johnston, I., Newsom-Davis, J. Calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Ann Neurol 1991, 29: 307-14.
31. Chalk, C.H., Murray, N.M.F., Newsom-Davis, J., O'Neill, J.H., Spiro, S.G. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990, 40: 1552-6.
32. Lundh, H., Nilsson, O., Rosén, I. Current therapy of the Lambert-Eaton myasthenic syndrome. In: Progress in Brain Research, Vol. 84. Aquilonius, S.-M., Gillberg, P.-G. (Eds.). Elsevier Science Publishers: Amsterdam 1990, 163-70.
33. Silbert, P.L., Hankey, G.J., Barr, A.L. Successful alternate day guanidine therapy following guanidine-induced neutropenia in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1990, 13: 360-1.
34. McEvoy, K.M., Windebank, A.J., Daube, J.R., Low, P.A. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. New Engl J Med 1989, 321: 1567-71.
35. Sanders, D.B., Howard, J.F. Jr., Massey, J.M. 3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis. Ann NY Acad Sci 1993, 681: 588-90.
36. Henze, T. Myasthenia gravis and myasthenic syndromes. Part I. Myasthenia gravis. Drugs of Today 1997, 33: 485-98.
37. Streib, E.W., Rothner, A.D. Eaton-Lambert myasthenic syndrome: Long-term treatment of three patients with prednisolone. Ann Neurol 1981, 10: 448-53.
38. Newsom-Davis, J., Murray, M.F. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton syndrome. Neurology 1984, 34: 480-5.
39. Ingram, D.A., Davis, G.R., Schwartz, M.S., Traub, M., Newland, A.C., Swash, M. Cancer-associated myasthenic (Eaton-Lambert) syndrome: Distribution of abnormality and effect of treatment. J Neurol Neurosurg Psychiatry 1984, 47: 806-12.
40. Engel, A.G. The investigation of congenital myasthenic syndromes. Ann NY Acad Sci 1993, 681: 425-34.
41. Hutchinson, D.O., Engel, A.G., Walls, T.J. et al. The spectrum of congenital end-plate acetylcholinesterase deficiency. Ann NY Acad Sci 1993, 681: 469-86.
42. Engel, A.G. Congenital disorders of neuromuscular transmission. Semin Neurol 1990, 10: 12-26.
43. Walls, T.J., Engel, A.G., Nagel, A.S., Harper, C.M., Trastek, V.F. Congenital myasthenic syndrome associated with paucity of synaptic vesicles and reducecd quantal release. Ann NY Acad Sci 1993, 681: 461-8.
44. Nagel, A., Engel, A.G., Walls, T.J., Harper, C.M., Waisburg, H.A. Congenital end-plate acetylcholine receptor deficiency and short channel open time. Ann NY Acad Sci 1993, 681: 509-14.
45. Engel, A.G. Newly recognized congenital myasthenic syndromes. Prog Brain Res 1990, 84: 125-37.
46. Uchitel, O., Engel, A.G., Walls, T.J., Nagel, A., Bril, V., Trastek, V.F. Congenital myasthenic syndrome attributed to an abnormal interaction of acetylcholine with its receptor. Ann NY Acad Sci 1993, 681: 487-96.
47. Engel, A.G., Hutchinson, D.O., Nakano, S. et al. Myasthenic syndromes attributed to mutations affecting the ε-subunit of the acetylcholine receptor. Ann NY Acad Sci 1993, 681: 496-508.
48. Engel, A.G., Lambert, E.H., Mulder, D.M. et al. A newly recognised congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann Neurol 1982, 11: 553-69.
49. Oosterhuis, H.J.G.H., Newsom-Davis, J., Wokke, J.J.H. The slow channel syndrome. Two new cases. Brain 1987, 110: 1061-79.
50. Gomez, C.M., Maselli, R., Gammack, J. et al. A β-subunit mutation in the acetylcholine receptor channel gate causes severe slow-channel syndrome. Ann Neurol 1996, 39: 712-23.
51. Van Ermengem, E. Über einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Z Hyg Infektionskh 1897, 26: 1-56.
52. Lamanna, C. The most poisonous poison. What do we know about the toxin of botulism? Science 1959, 130: 763-72.
53. Wainwright, R.B., Heyward, W.L., Middaugh, J.P., Hatheway, C.L., Harpster, A.P., Bender T.R. Food-borne botulism in Alaska 1947-1985: Epidemiology and clinical findings. J Infect Dis 1988, 157: 1158-62.
54. Roblot, P., Roblot, F., Fauchere, H.L. et al. Retrospective study of 108 cases of botulism in Poitiers, France. J Med Microbiol 1994, 40: 379-84.
55. Schiavo, G., Rossetto, O., Tonello, F., Montecucco, C. Intracellular targets and metalloprotease activity of tetanus and botulism neurotoxins. Curr Top Microbiol Immunol 1995, 195: 257-74.
56. Woodruff, B.A., Griffin, P.M., McCroskey, L.J. et al. Clinical and laboratory comparison of botulism from toxin types A, B and E in the United States, 1975-1988. J Infect Dis 1992, 166: 1281-6.
57. Goode, G.B., Shearn, D.L. Botulism: A case with associated sensory abnormalities. Arch Neurol 1982, 39: 55.
58. Martínez-Castillo, J.C., Del Real, M.A., Hernández-González, A., De Blas, G., Alvarez-Cermeno, J.C. Botulism with sensory symptoms: A second case. J Neurol Neurosurg Psychiatry 1991, 54: 844-5.
59. Cherington, M. Botulism. Semin Neurol 1990, 10: 27-31.
60. Hatheway, C.L. Botulism. In: Laboratory Diagnosis of Infectious Diseases: Principles and Practice, Vol. 1. Balows, A., Hausler, W.H. Jr., Ohashi, M., Turano, A. (Eds.). Springer: Berlin 1988.
61. Thomas, R.J. Detection of Clostridium botulinum types C and D toxin by ELISA. Aust Vet J 1991, 68: 111-3.
62. Szabo, E.A., Pemberton, J.M., Gibson, A.M., Eyles, M.J., Desmarchelier P.M. Polymerase chain reaction for detection of Clostridium botulinum types A, B and E in food, soil and infant faeces. J Appl Bacteriol 1994, 76: 539-45.
63. Cherington, M., Ryan, D.W. Treatment of botulism with guanidine. Early neurophysiologic studies. New Engl J Med 1970, 282: 195-7.
64. Davis, L.E., Johnson, J.K., Bicknell, J.M., Levy, H., McEvoy, K.M. Human type A botulism and treatment with 3,4-diaminopyridine. Electromyogr Clin Neurophysiol 1992, 32: 379-83.
65. Neal, K.R., Dunbar, E.M. Improvement in bulbar weakness with guanoxan in type B botulism. Lancet 1990, 335: 1286-7.
66. Henze, T., Prange, H. Severe form of botulism by toxin type A. Deutsch Med Wschr 1983, 108: 185-7.